As reported on Inside Precision Medicine, for years, a chronic spinal cord injury (SCI) has felt like a permanent biological roadblock. When the spinal cord is damaged, the immediate aftermath—known as the subacute phase (the weeks right after the injury)—is highly volatile but offers a brief window where the tissue is still relatively receptive to healing. Once an injury settles into the chronic phase (months or years down the line), dense scar tissue forms, and surviving nerve fibers lose their protective coating, leaving patients with long-term, stubborn paralysis.

But a groundbreaking approach presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting is shifting the paradigm.

Led by Hideyuki Okano, MD, PhD, a pioneering researcher at Keio University in Japan, scientists are preparing to launch a clinical trial aimed specifically at repairing these long-standing, chronic injuries. Instead of trying to rebuild the entire spinal cord from scratch, this therapy focuses on a much more practical goal: repairing the “electrical insulation” of the nerve pathways that survived the initial accident.

The Biology: Fixing the Insulation, Not Just the Wires

To understand why this new therapy is a big deal, it helps to look at how our nerves send signals. Think of your spinal cord as a massive bundle of electrical cables. Each nerve fiber is wrapped in a protective, fatty sheath called myelin. Myelin acts exactly like the plastic insulation on a power cord—it keeps the electrical signals moving fast and prevents them from dissipating.

In a chronic, incomplete spinal cord injury, many nerve pathways actually survive. The problem is they lose their myelin insulation (a process called demyelination). Without it, the nerves are like bare, exposed wires—they are physically intact, but they can’t transmit signals to or from the brain.

To tackle this, Dr. Okano’s team is using induced pluripotent stem cells (iPSCs)—adult cells (like skin cells) that have been scientifically reprogrammed back into an embryonic-like state, allowing them to turn into virtually any cell type.

While their earlier research focused on cells that generate brand-new neurons, this chronic-phase therapy uses a highly specialized cell type: gliogenic neural stem/progenitor cells (gNS/PCs).

Instead of making new neurons, these cells are primed to develop into support cells:

• Oligodendrocytes: The specialized cells responsible for wrapping nerves in fresh myelin.
• Astrocytes: Star-shaped cells that nourish, protect, and maintain the surrounding nerve environment.

By transplanting these helper cells, the therapy aims to “re-insulate” the surviving, dormant pathways, essentially turning the power back on in circuits that have been quiet for years.

From “Safety First” to Reversing Paralysis

This upcoming trial isn’t starting from scratch; it is built on a decade of rigorous research. Dr. Okano’s team previously made headlines by launching the world’s first clinical study using iPSC-derived cells to treat patients in the subacute phase of spinal cord injury.

In March 2025, the team shared encouraging one-year follow-up results from that initial four-patient safety trial. The results were incredibly promising:

• Zero serious side effects: There were no treatment-related adverse events, proving the safety of transplanting these reprogrammed cells into human spines.
• Real neurological progress: Two of the four patients showed notable physical improvements. Remarkably, one patient even regained the ability to stand independently and begin walking exercises (gait training).

While those subacute results are still awaiting formal peer review, they provided the rock-solid safety foundation needed to take on the much tougher challenge of chronic injuries.

As Dr. Okano explained during his presentation:

“We have already successfully completed a world-first, first-in-human clinical study targeting patients in the subacute phase, which demonstrated a promising safety profile. Our shift to the chronic phase is the next logical milestone, built upon that solid foundation. Since the cellular environment changes over time, we are evolving our strategy from just establishing safety to actively overcoming the stubborn, long-standing barriers of chronic paralysis.”

What Lies Ahead

In lab studies, these clinical-grade helper cells have done exactly what scientists hoped. When transplanted into animal models with chronic spinal cord injuries, the cells successfully integrated, promoted the rebuilding of myelin (remyelination), kept existing nerve fibers from dying, and significantly improved the animals’ physical movement—all without showing any signs of forming tumors or unwanted tissue.

The team is now preparing to transition this success to humans. The physician-initiated clinical trial is scheduled to begin recruiting patients in 2027. It will specifically target individuals living with chronic, incomplete spinal cord injuries who still have those inactive, demyelinated nerve fibers waiting to be repaired.

While there is still a long road of testing ahead, this shift in strategy—focusing on restoring the cellular support system rather than forcing the body to grow entirely new spinal cord pathways—represents a massive step forward for regenerative medicine and offers a genuine beacon of hope for those living with long-term paralysis.